Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Yunnan Baiyao To Develop Cosmetic Medicine Business

This article was originally published in PharmAsia News

Executive Summary

Yunnan Baiyao Group is planning to pursue the cosmetic medical market in China after its toothpaste foray three years ago saw sales surpassing 600 million yuan. The company and Japan's Maleave Cosmetics recently signed a cosmetic technology transfer agreement, paving the way for Yunnan Baiyao to consolidate the daily chemical business into a key growth area. Analysts observe that drug firms have an edge in developing cosmetic medical products. Many pharmaceutical corporations such as Pientzehuang and Shenghuo Pharmaceutical are gearing toward this field to boost profits. Figures show that the sector is expected to grow by 20 percent when total cosmetic sales in China hit 120 billion yuan by 2010. (Click here for more - Chinese language)

You may also be interested in...



Guardant Health Expects FDA Approval Of Liquid Biopsy Test Will Strengthen Coverage, Adoption

Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.

Finance Watch: CureVac’s IPO Is Ready For Launch

Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m. 

US FDA's Hahn Promotes Provider Role In Boosting Public Confidence In COVID-19 Products

Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel